"Molybdenum" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A metallic element with the atomic symbol Mo, atomic number 42, and atomic weight 95.95. It is an essential trace element, being a component of the enzymes xanthine oxidase, aldehyde oxidase, and nitrate reductase.
| Descriptor ID |
D008982
|
| MeSH Number(s) |
D01.268.556.555 D01.268.956.500 D01.552.544.555
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Molybdenum".
Below are MeSH descriptors whose meaning is more specific than "Molybdenum".
This graph shows the total number of publications written about "Molybdenum" by people in this website by year, and whether "Molybdenum" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 0 | 1 | 1 |
| 2001 | 1 | 0 | 1 |
| 2011 | 1 | 0 | 1 |
| 2013 | 0 | 1 | 1 |
| 2018 | 1 | 0 | 1 |
| 2022 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Molybdenum" by people in Profiles.
-
Urinary metals, arsenic, and polycyclic aromatic hydrocarbon exposure and risk of chronic bronchitis in the US adult population. Environ Sci Pollut Res Int. 2022 Oct; 29(48):73480-73491.
-
Development of a rapid UPLC-MS/MS determination of urine sulfocysteine for diagnosis of sulfocysteinuria and molybdenum co-factor deficiencies. Bioanalysis. 2018 May 01; 10(10):747-756.
-
3,4-Dihydroxy-5-nitrobenzaldehyde (DHNB) is a potent inhibitor of xanthine oxidase: a potential therapeutic agent for treatment of hyperuricemia and gout. Biochem Pharmacol. 2013 Nov 01; 86(9):1328-37.
-
Azotobacter vinelandii gene clusters for two types of peptidic and catechol siderophores produced in response to molybdenum. J Appl Microbiol. 2011 Oct; 111(4):932-8.
-
A non-comparative randomized phase II study of 2 doses of ATN-224, a copper/zinc superoxide dismutase inhibitor, in patients with biochemically recurrent hormone-na?ve prostate cancer. Urol Oncol. 2013 Jul; 31(5):581-8.
-
A computational framework for proteome-wide pursuit and prediction of metalloproteins using ICP-MS and MS/MS data. BMC Bioinformatics. 2011 Feb 28; 12:64.
-
YcbX and yiiM, two novel determinants for resistance of Escherichia coli to N-hydroxylated base analogues. Mol Microbiol. 2008 Apr; 68(1):51-65.
-
Treatment of Wilson disease with ammonium tetrathiomolybdate: IV. Comparison of tetrathiomolybdate and trientine in a double-blind study of treatment of the neurologic presentation of Wilson disease. Arch Neurol. 2006 Apr; 63(4):521-7.
-
Thickness of molybdenum filter and squared contrast-to-noise ratio per dose for digital mammography. AJR Am J Roentgenol. 2005 Oct; 185(4):960-3.
-
In vitro cytotoxicity of nanoparticles in mammalian germline stem cells. Toxicol Sci. 2005 Dec; 88(2):412-9.